Author: Hoffmann, Steve; Cepok, Sabine; Grummel, Verena; Lehmann-Horn, Klaus; Hackermueller, Jörg; Stadler, Peter F.; Hartung, Hans-Peter; Berthele, Achim; Deisenhammer, Florian; Wasmuth, Ralf; Hemmer, Bernhard
Title: HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis Cord-id: 3lwrn2fi Document date: 2008_8_1
ID: 3lwrn2fi
Snippet: The formation of antibodies to interferon-beta (IFN-β), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-β. In two independent continuous and binary-trait association studies, HLA-DR
Document: The formation of antibodies to interferon-beta (IFN-β), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-β. In two independent continuous and binary-trait association studies, HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 (odds ratio: 5.15)—but not other HLA alleles—were strongly associated with the development of binding and neutralizing antibodies to IFN-β. The associated HLA-DRB1(∗)04 alleles differ from nonassociated HLA-DRB1(∗)04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1(∗)0401 and (∗)0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-β. In summary, we identified genetic factors determining the immunogenicity of IFN-β, a protein-based disease-modifying agent for the treatment of MS.
Search related documents:
Co phrase search for related documents- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and low frequency: 1, 2, 3, 4, 5, 6
- absence presence and low number: 1, 2, 3
- absence presence and low resolution: 1
- absence presence and lung carcinoma: 1
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- activity determine and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- activity determine and lysis buffer: 1
- acute respiratory syndrome and administration preparation: 1
- acute respiratory syndrome and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute respiratory syndrome and low immunogenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62
- acute respiratory syndrome and low resolution: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory syndrome and low resolution analysis: 1
- acute respiratory syndrome and lung carcinoma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory syndrome and lysis buffer: 1, 2, 3
- administration preparation and low number: 1
- low number and lung carcinoma: 1, 2
- low number and lysis buffer: 1
Co phrase search for related documents, hyperlinks ordered by date